Pre0905- Randomized Trial Of Gilteritinib Vs Midostaurin In Flt3 Mutated Acute Myeloid Leukemia (Aml)
Posted Date: Dec 19, 2020
- Investigator: Emily Curran
- Specialties: Cancer, Leukemia, Oncology
- Type of Study: Drug
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AM. Patients will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation.
Criteria:
To Be Eligible: Must Have Previously Untreated Flt3 Mutated Non M3 Aml , Adequate Organ Function, Ecog 0-3, No Cns Leukemia, No Hypomethylating Agent Within 21 Days, No Other Malignancy, No Uncontrolled Cardiac Issues Or Infection, No Hypersensitivity To
Keywords:
Leukemia, Aml, Acute Myeloid Leukemia
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com